AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30646139 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure telemonitoring with pharmacist management
Number of subjects: 450
Study 30646139 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 450
Study 30402599 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial whey hydrolysate infant formula
Number of subjects: 2252
Study 30402599 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive whey hydrolysate infant formula
Number of subjects: 2252
Study 30402599 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive casein hydrolysate infant formula
Number of subjects: 2252
Study 30402599 — intervention group
Group type: COMPARATOR
Intervention: Standard cow's milk formula
Number of subjects: 2252
Study 23557321 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-specific behaviour change strategy to improve child nutrition
Number of subjects: 750
Study 24074642 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg once daily)
Number of subjects: 822
Study 24074642 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir (400 mg twice daily)
Number of subjects: 822
Study 21222223 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility-toning-balance exercise
Number of subjects: 179
Study 21222223 — intervention group
Group type: COMPARATOR
Intervention: Walking exercise
Number of subjects: 179
Study 19062012 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral contraceptive alone
Number of subjects: 58
Study 19062012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive combined with a GnRH analog
Number of subjects: 58
Study 17925591 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 531 (0.3, 1, or 2 microg/kg)
Number of subjects: 30
Study 17925591 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 531 (1 microg/kg)
Number of subjects: 30
Study 17925591 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 531 (2 microg/kg)
Number of subjects: 30
Study 17925591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15026950 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-body hyperthermia with a radiofrequency multiantenna applicator (BSD 2000/3D) under MR monitoring
Number of subjects: 33
Study 11722711 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clobetasol propionate ointment (0.05%) applied three times a day
Number of subjects: 54
Study 11722711 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate in an adhesive denture paste (1:1) applied two times a day
Number of subjects: 54
Study 11722711 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate in an oral analgesic base (Orabase‐B) (1:1) applied two times a day
Number of subjects: 54
Study 8989238 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (12.5 micrograms/kg per day)
Number of subjects: 173
Study 8989238 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 173
Study 8480572 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous preprocedural heparinization for > or = 12 hours
Number of subjects: 0
Study 8480572 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preprocedural heparin)
Number of subjects: 0
Study 2953219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafazatrom 800 mg four times daily for 1 week
Number of subjects: 12
Study 2953219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafazatrom 1600 mg four times daily for 1 week
Number of subjects: 12
Study 2953219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafazatrom treatment
Number of subjects: 12
Study 29769450 — intervention group
Group type: EXPERIMENTAL
Intervention: HSPPC‐96 vaccination in combination with standard treatment after surgical resection
Number of subjects: 20
Study 29769450 — intervention group
Group type: EXPERIMENTAL
Intervention: HSPPC‐96 vaccination
Number of subjects: 20
Study 26519244 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-ventricle-to-pulmonary-artery shunt (RVPAS)
Number of subjects: 323
Study 26519244 — intervention group
Group type: COMPARATOR
Intervention: Modified Blalock-Taussig shunt (MBTS)
Number of subjects: 323
Study 26519244 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hypothermic circulatory arrest
Number of subjects: 323
Study 26519244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Fontan complications
Number of subjects: 323
Study 26519244 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at stage II
Number of subjects: 323
Study 26519244 — intervention group
Group type: EXPERIMENTAL
Intervention: At least moderate tricuspid regurgitation
Number of subjects: 323
Study 25415811 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (30mg/kg)
Number of subjects: 30
Study 25415811 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study 24351700 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 417
Study 24351700 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (≥10% body weight loss)
Number of subjects: 417
Study 24351700 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in weight
Number of subjects: 417
Study 24351700 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline level of the biomarker
Number of subjects: 417
Study 19395425 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 157
Study 19395425 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 157
Study 18391619 — intervention group
Group type: EXPERIMENTAL
Intervention: New prognostic classification based on residual disease after neoadjuvant chemotherapy
Number of subjects: 710
Study 15879583 — intervention group
Group type: EXPERIMENTAL
Intervention: TSD + paroxetine
Number of subjects: 80
Study 15879583 — intervention group
Group type: EXPERIMENTAL
Intervention: TSD + PBO
Number of subjects: 80
Study 15879583 — intervention group
Group type: COMPARATOR
Intervention: paroxetine alone
Number of subjects: 80
Study 14526714 — intervention group
Group type: EXPERIMENTAL
Intervention: CHM extract capsule (containing 18 herbs), given daily for 8 weeks
Number of subjects: 55
Study 14526714 — intervention group
Group type: COMPARATOR
Intervention: Placebo, given daily for 8 weeks
Number of subjects: 55
Study 14526714 — intervention group
Group type: EXPERIMENTAL
Intervention: CHM extract capsule
Number of subjects: 55
Study 14526714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 10392679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF group; n = 21)
Number of subjects: 43
Study 10392679 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 22)
Number of subjects: 43
Study 8879380 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ifosfamide (OSI) at a dose of 1 g/day for 14 days every 4 weeks
Number of subjects: 68
Study 8879380 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ifosfamide (IVI) at a dose of 1.6 g/m2/day for 5 days every 4 weeks
Number of subjects: 68
Study 8879380 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ifosfamide (OSI)
Number of subjects: 68
Study 8879380 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ifosfamide (IVI)
Number of subjects: 68
Study 1848054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Enoxaparin), 30 mg subcutaneously twice daily for 14 days or until discharge.
Number of subjects: 665
Study 1848054 — intervention group
Group type: COMPARATOR
Intervention: Standard calcium heparin, 7500 units subcutaneously twice daily for 14 days or until discharge.
Number of subjects: 665
Study 6395416 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback
Number of subjects: 30
Study 6395416 — intervention group
Group type: COMPARATOR
Intervention: Occlusal appliances (splints)
Number of subjects: 30
Study 6395416 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 30
Study 6395416 — intervention group
Group type: COMPARATOR
Intervention: Night-time use of stabilisation splints
Number of subjects: 30
Study 6395416 — intervention group
Group type: COMPARATOR
Intervention: Night-time use of bite plates
Number of subjects: 30
Study 6395416 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAS scores (anxiety level)
Number of subjects: 30
Study 6395416 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG activity in masseter and temporal muscles
Number of subjects: 30
Study 31022366 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 0
Study 31022366 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination instruments (hearing aids with a built-in sound generator)
Number of subjects: 0
Study 31022366 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29651778 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up administered by specialist nurses
Number of subjects: 259
Study 29651778 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital outpatient follow-up
Number of subjects: 259
Study 29651778 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 259
Study 26849442 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observation of treatment (DOT) provided by a family member
Number of subjects: 624
Study 26849442 — intervention group
Group type: COMPARATOR
Intervention: Direct observation of treatment (DOT) provided by a non-family member (usual-practice)
Number of subjects: 624
Study 24467828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen (1 to 3 years)
Number of subjects: 563
Study 24467828 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 563
Study 22781788 — intervention group
Group type: EXPERIMENTAL
Intervention: VMS frequency (24-hour, day, and night)
Number of subjects: 145
Study 22781788 — intervention group
Group type: EXPERIMENTAL
Intervention: VMS frequency (24-hour)
Number of subjects: 145
Study 22781788 — intervention group
Group type: EXPERIMENTAL
Intervention: Day VMS frequency
Number of subjects: 145
Study 22781788 — intervention group
Group type: EXPERIMENTAL
Intervention: Night VMS frequency
Number of subjects: 145
Study 20100767 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of both clinical seizures and subclinical seizure patterns (group A)
Number of subjects: 33
Study 20100767 — intervention group
Group type: COMPARATOR
Intervention: Control group (blinding of aEEG registration and treatment of clinical seizures only, group B)
Number of subjects: 33
Study 20100767 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 33
Study 20100767 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (group A)
Number of subjects: 33
Study 20100767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 16200053 — intervention group
Group type: EXPERIMENTAL
Intervention: Early trabeculectomy
Number of subjects: 60
Study 16200053 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management
Number of subjects: 60
Study 16200053 — intervention group
Group type: COMPARATOR
Intervention: Educational package about glaucoma
Number of subjects: 60
Study 12898290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein repair
Number of subjects: 150
Study 12898290 — intervention group
Group type: EXPERIMENTAL
Intervention: McVay repair
Number of subjects: 150
Study 12898290 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 150
Study 11513014 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention (viewing a video on AD, reading written information about the disease, or both)
Number of subjects: 100
Study 11513014 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education intervention)
Number of subjects: 100
Study 9573908 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help course
Number of subjects: 193
Study 9573908 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty management
Number of subjects: 193
Study 9573908 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help course plus uncertainty management
Number of subjects: 193
Study 9573908 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 193
Study 7835776 — intervention group
Group type: COMPARATOR
Intervention: Loop excision (n = 38)
Number of subjects: 90
Study 7835776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-knife conization (n = 52)
Number of subjects: 90
Study 2899840 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg per day, n = 1234)
Number of subjects: 2466
Study 2899840 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1232)
Number of subjects: 2466
Study 2899840 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem in patients without pulmonary congestion (n = 1909)
Number of subjects: 2466
Study 2899840 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem in patients with pulmonary congestion (n = 490)
Number of subjects: 2466
Study 31270933 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction trees (IT)
Number of subjects: 0
Study 31270933 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous threshold interaction modeling algorithm (STIMA)
Number of subjects: 0
Study 31270933 — intervention group
Group type: EXPERIMENTAL
Intervention: Model‐based recursive partitioning
Number of subjects: 0
Study 31270933 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup identification based on differential effect
Number of subjects: 0
Study 31270933 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive refinement by directed peeling
Number of subjects: 0
Study 31270933 — intervention group
Group type: COMPARATOR
Intervention: None of the methods
Number of subjects: 0
Study 29473382 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin Succinate (SS), 5 mg once a day for 12 weeks
Number of subjects: 90
Study 29473382 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and Alternative Medicine (CAM), 930 mg twice daily for 12 weeks
Number of subjects: 90
Study 25152207 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine plus PegIFN alpha‐2a (combination therapy)
Number of subjects: 159
Study 25152207 — intervention group
Group type: COMPARATOR
Intervention: Telbivudine monotherapy
Number of subjects: 159
Study 25152207 — intervention group
Group type: COMPARATOR
Intervention: PegIFN alpha‐2a monotherapy
Number of subjects: 159
Study 23084597 — intervention group
Group type: EXPERIMENTAL
Intervention: MICA v4 scale
Number of subjects: 191
Study 21211688 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-detected atrial tachycardia (AT) or atrial fibrillation (AF) >10 min
Number of subjects: 1193
Study 21211688 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite end point (deaths or HF hospitalizations)
Number of subjects: 1193
Study 21211688 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-detected AT/AF
Number of subjects: 1193
Study 21211688 — intervention group
Group type: EXPERIMENTAL
Intervention: New York Heart Association functional class III or IV compared with II
Number of subjects: 1193
Study 21211688 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of beta-blockers
Number of subjects: 1193
Study 21211688 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 1193
Study 18241759 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (carotid artery stenting)
Number of subjects: 2985
Study 18241759 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (carotid endarterectomy)
Number of subjects: 2985
Study 16167251 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanoreine
Number of subjects: 80
Study 16167251 — intervention group
Group type: COMPARATOR
Intervention: Control (no titanoreine)
Number of subjects: 80
Study 12491829 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding (EEF)
Number of subjects: 28
Study 12491829 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition plus enteral feeding (TPN + EF)
Number of subjects: 28
Study 9751347 — intervention group
Group type: EXPERIMENTAL
Intervention: Boxer shorts
Number of subjects: 97
Study 9751347 — intervention group
Group type: COMPARATOR
Intervention: Brief style underwear
Number of subjects: 97
Study 9751347 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover group (changed underwear type)
Number of subjects: 97
Study 7714474 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherent motion discrimination based on direction
Number of subjects: 0
Study 7714474 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherent motion discrimination based on speed
Number of subjects: 0
Study 7714474 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sensitivity to coherent motion strength
Number of subjects: 0
Study 7714474 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing of direction and speed information
Number of subjects: 0
Study 2651586 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 52
Study 2651586 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 52
Study 2651586 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment in semicomatose/stuporous patients
Number of subjects: 52
Study 2651586 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment in semicomatose/stuporous patients
Number of subjects: 52
Study 328033 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 375 mg twice daily
Number of subjects: 740
Study 328033 — intervention group
Group type: COMPARATOR
Intervention: Glafenin 200 mg three times daily
Number of subjects: 740
Study 328033 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 740
Study 328033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 740
Study 30527775 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2199
Study 30527775 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin–warfarin
Number of subjects: 2199
Study 29657693 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 70
Study 29657693 — intervention group
Group type: COMPARATOR
Intervention: Routine psychological counseling services (Control)
Number of subjects: 70
Study 25742985 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 25
Study 25742985 — intervention group
Group type: COMPARATOR
Intervention: Interferon‐β/glatiramer acetate
Number of subjects: 25
Study 23505993 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive-behavioral group therapy for anxiety
Number of subjects: 84
Study 21516035 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate Practice (DP) group
Number of subjects: 26
Study 21516035 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 19318674 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened AMP challenge
Number of subjects: 18
Study 19318674 — intervention group
Group type: COMPARATOR
Intervention: Standard AMP challenge
Number of subjects: 18
Study 19318674 — intervention group
Group type: COMPARATOR
Intervention: Repeated shortened AMP challenges
Number of subjects: 18
Study 16714767 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative fluid management strategy
Number of subjects: 1000
Study 16714767 — intervention group
Group type: COMPARATOR
Intervention: Liberal fluid management strategy
Number of subjects: 1000
Study 15449262 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation
Number of subjects: 1454
Study 15449262 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 1454
Study 15449262 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation with polyethylene glycol (PEG)
Number of subjects: 1454
Study 15449262 — intervention group
Group type: EXPERIMENTAL
Intervention: Other bowel preparations
Number of subjects: 1454
Study 11722295 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimation
Number of subjects: 0
Study 11722295 — intervention group
Group type: EXPERIMENTAL
Intervention: Goniometry
Number of subjects: 0
Study 11722295 — intervention group
Group type: EXPERIMENTAL
Intervention: Still photography
Number of subjects: 0
Study 11722295 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand behind back reach
Number of subjects: 0
Study 11722295 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand and reach
Number of subjects: 0
Study 9143391 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-1 alpha (rhuIL-1 alpha) at doses of 0.1-10 micrograms/m2 for 4 days by subcutaneous injection before ICF chemotherapy
Number of subjects: 27
Study 9143391 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-1 alpha (rhuIL-1 alpha) administered after ICE chemotherapy
Number of subjects: 27
Study 9143391 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard chemotherapy without rhuIL-1 alpha
Number of subjects: 27
Study 8106800 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium treatment
Number of subjects: 25
Study 8106800 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 3115350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 42
Study 3115350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31961303 — intervention group
Group type: EXPERIMENTAL
Intervention: TPHD-LAMP for T. pallidum
Number of subjects: 293
Study 31961303 — intervention group
Group type: EXPERIMENTAL
Intervention: TPHD-LAMP for H. ducreyi
Number of subjects: 293
Study 30167701 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway device (SGA)
Number of subjects: 9296
Study 30167701 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation (TI)
Number of subjects: 9296
Study 27917213 — intervention group
Group type: EXPERIMENTAL
Intervention: Early skin-to-skin contact (SSC)
Number of subjects: 200
Study 27917213 — intervention group
Group type: COMPARATOR
Intervention: Control (radiant warmer)
Number of subjects: 200
Study 25005193 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary pterygium surgery
Number of subjects: 40
Study 25005193 — intervention group
Group type: COMPARATOR
Intervention: Recurrent pterygium surgery
Number of subjects: 40